Shareholders of unichem laboratories have approved the reappointment of Pabitrakumar Bhattacharyya as Managing Director and Chief Executive Officer, alongside adopting the audited financial statements for the fiscal year ended March 31, 2026. The resolutions were passed at the company’s 63rd Annual General Meeting (AGM), which concluded without any qualifications from statutory or secretarial auditors.

The meeting was held on Tuesday, August 11, 2026, via video conference in compliance with circulars issued by the Ministry of Corporate Affairs (MCA) and the Securities and Exchange Board of India (SEBI). Due to personal reasons, Dr. Prakash A. Mody, Chairman of the Board, could not attend. At the request of other directors present, Mr. Pranay Godha, Non-Executive Director, consented to act as Chairman and presided over the session. Representatives from Statutory Auditors N.A. Shah Associates LLP and Secretarial Auditors Alwyn Jay & Co. were present to address queries.

Key Resolutions Passed

The Board placed several ordinary and special business items before the members for consideration. All resolutions were successfully passed during the proceedings.

Pabitrakumar Bhattacharyya, who retires by rotation, offered himself for re-appointment as a director. Subsequently, shareholders approved his specific re-appointment as Managing Director and Chief Executive Officer through a special resolution. The meeting also ratified the remuneration payable to Kishore Bhatia & Associates (Firm Registration No. 00294) for the year ended March 31, 2027.

Governance and Compliance

The Company Secretary, Pradeep Gautam Bhandari, informed members that the Statutory Auditors’ Report and the Secretarial Auditor’s report contained no qualifications. The Managing Director presented a speech on the current market scenario and its impact on business performance, which was noted by shareholders.

E-voting was conducted through the National Securities Depository Limited (NSDL) platform. Mr. Alwyn D'Souza, Practicing Company Secretary (CP No.: 5137; Membership No. 5559), served as the scrutinizer for the e-voting process. The proxy register was not available for inspection as the facility for appointing proxies is not applicable for meetings held entirely through video conference. The meeting commenced at 3:30 p.m. and concluded at 4:11 p.m. after requisite quorum was established and all business transacted.

Unichem Laboratories reported a consolidated net profit of ₹41.47 crore for the quarter ended June 30, 2026, marking a significant turnaround from the net loss of ₹10.47 crore recorded in the corresponding quarter of FY25. The profitability shift was primarily driven by a 20.1% year-on-year increase in revenue from operations, which stood at ₹632.62 crore compared to ₹526.60 crore in Q1FY25. This revenue growth, coupled with effective cost management, resulted in an EBITDA margin expansion to 11% from 4.3% in the prior year period, signaling improved operational efficiency within the pharmaceutical segment.

The Board of Directors approved the unaudited consolidated and standalone financial statements during a meeting held on August 11, 2026. The results were reviewed by N. A. Shah Associates LLP, the statutory auditors, who issued an unmodified conclusion pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The standalone results also reflected this positive trend, with the company reporting a profit after tax of ₹5.53 crore, contrasting with a loss of ₹1.85 crore in the previous year's quarter.

Financial Performance Highlights

The following table summarises key consolidated financial metrics for the quarter alongside prior year comparatives and the full year ended March 2026:

Consolidated total income reached ₹648.23 crore, aided by other income rising to ₹15.61 crore from ₹6.82 crore in the prior year period. Total expenses increased moderately by 10.5% to ₹599.24 crore, indicating effective cost management despite higher operational volumes. Key expense components included cost of materials consumed at ₹190.02 crore and employee benefits expense at ₹103.31 crore.

Standalone Results and Subsidiary Contributions

On a standalone basis, Unichem Laboratories reported revenue from operations of ₹366.27 crore, a slight decline from ₹384.25 crore in Q1FY25. However, the entity turned profitable with a net profit of ₹5.53 crore, up from a loss of ₹1.85 crore. Standalone earnings per share stood at ₹0.79, compared to a loss of ₹0.26 per share in the previous year.

The auditor's report noted that subsidiaries Niche Generics Limited (UK) and Unichem Pharmaceuticals (USA), Inc. contributed significantly to the group's performance. These entities reported combined revenues of ₹470.28 crore and a net profit of ₹12.39 crore for the quarter. Other overseas subsidiaries, including entities in South Africa, Brazil, and China, contributed ₹23.59 crore in revenues. Additionally, during the quarter, the company invested USD 80,000 (equivalent to ₹0.76 crore) towards redeemable preference shares in its wholly owned subsidiary, Unichem (China) Pvt Ltd.

What the Numbers Show

The divergence between consolidated and standalone performance highlights the critical role of international operations in Unichem's profitability model. While the Indian parent entity saw flat revenue growth, the consolidated figures reflect strong international demand, particularly from its UK and US subsidiaries. The sharp expansion in EBITDA margin — from 4.3% to 11% — further underscores improved operating leverage across the group.

Notably, there were no exceptional items impacting the current quarter's bottom line, contrasting with the prior year's accounting adjustments related to European Commission fines and labor code provisions. Management continues to monitor developments pertaining to the New Labour Codes, which had resulted in a one-time provision of ₹15.40 crore in the previous fiscal year. The company also settled a European Commission fine demand of Euro 19.55 million in October 2025, with the interest component recognised as an exceptional item in FY26. No current tax charge was levied for the period due to the set-off of unabsorbed tax depreciation and business losses.